Lyra Therapeutics announces results from BEACON Phase 2 study of LYR-220

Lyra Therapeutics announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery. The study met its primary safety endpoint, with no serious adverse events observed. Most commonly reported adverse events included sinusitis, nasopharyngitis, bronchitis, and COVID-19. LYR-220 significantly improved important patient reported outcome measures compared to sham control: Statistically significant improvement in a composite of the 3 cardinal symptoms of CRS at week 24; Statistically significant improvements in Sino-Nasal Outcome Test score compared to sham control at week 24; Statistically significant improvement in a composite of the 3 cardinal symptoms of CRS as early as week 4; Statistically significant improvements in SNOT-22 were observed as early as week 2; Improvements in SNOT-22 were sustained throughout the study and clinically meaningful with almost twice the minimal clinically important difference observed at week 24 compared to sham. LYR-220 is a bioresorbable nasal matrix designed to deliver six months of continuous anti-inflammatory medication to the sinonasal passages for the treatment of CRS. Topline results from the BEACON study of LYR-220 will be presented at the American Rhinologic Society 69th Annual Meeting on September 30, 2023, in Nashville, TN. Full results will be submitted for future publication.